# Discovery and characterization of protective Influenza Type B Virus neuraminidase antibodies

> **NIH NIH K01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $122,850

## Abstract

Project Summary/Abstract
 Influenza causes an estimated 1 billion cases yearly, with severe cases leading to fatal
bronchopneumonia, particularly in vulnerable populations. Influenza virions express two major surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), the latter of which is of interest due to its role in
viral egress and cleavage from mucus. Currently, the only FDA-approved antivirals used to treat influenza are
neuraminidase inhibitors, which are ineffective against some strains. Monoclonal antibodies (mAbs) directed at
NA provide an alternative therapeutic candidate. Delivering NA mAbs to the respiratory mucosal surface,
where the virus replicates, is a novel delivery method that could improve drug efficacy and patient compliance.
This five-year research career development award will provide training and development of the skills necessary
for the candidate to establish an independent research laboratory focused on understanding how human
antibodies against influenza can be harnessed to treat and prevent disease and transmission in animal
models. Currently, the candidate is a veterinarian and a graduate trainee at the Vanderbilt Vaccine Center who
will transition to an assistant professor position on the physician-scientist track in July 2024. Her training to
date has focused on the isolation and characterization of human monoclonal antibodies (mAbs) from subjects
with prior influenza history and mouse models of therapy. She will supplement this experience with further
training in developing in vivo ferret and ex vivo human tissue models of influenza infection with which to study
the natural pathogenesis of this virus and how human mAbs bind influenza to reduce pathogenesis. The short-
term goals of the proposed studies are to test the central hypothesis that neuraminidase-directed antibodies
play a significant role in the protective immune response and can be harnessed with antibody therapeutics.
This training will be supported by mentoring from national experts in the study of human antibodies (James
Crowe, Jr., Ivelin Georgiev), human airway epithelial cultures (Timothy Blackwell), influenza vaccinology
(Spyros Kalams), and small animal models of virus infection and pathology (Katherine Gibson-Corley). The
applicant aims to 1) elucidate the mechanisms of influenza type B (IBV) inhibition by mAbs specific to the
neuraminidase (NA) glycoprotein to test the hypotheses that NA antibodies exert distinct mechanisms of
protection, 2) use a human airway model of IBV infection to determine how NA mAbs in the presence of mucus
behave, 3) and test these mAbs in a ferret model of intranasal delivery to test the hypothesis that NA mAbs
delivered topically can reduce viral load and shedding. Overall, these studies will help define the role of IBV NA
antibodies and the mechanism of delivering mAbs to the respiratory mucosal surface. Industry groups are
developing protective mAbs made by the candidate as human therapeutic agents. Thus...

## Key facts

- **NIH application ID:** 11163147
- **Project number:** 7K01OD036063-02
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Rachael Wolters
- **Activity code:** K01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $122,850
- **Award type:** 7
- **Project period:** 2024-08-07 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11163147

## Citation

> US National Institutes of Health, RePORTER application 11163147, Discovery and characterization of protective Influenza Type B Virus neuraminidase antibodies (7K01OD036063-02). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/11163147. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*